Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 103.43B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 16.28 |
| Forward PE | 10.28 |
| Dividend | 3.92 (4.64%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 2,004,635 |
| Average Volume | 1,785,152 |
| Open | 84.30 |
| Previous Close | 84.57 |
| Day's Range | 84.30 - 85.86 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 43.29 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”).
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
LONDON--(BUSINESS WIRE)-- #AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic anti...
Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Sanofi SA at Citi Global Healthcare Conference Transcript
Sanofi SA at Citi Global Healthcare Conference Transcript
Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Why Falcon's Beyond Stock Is Jumping Today
Falcon’s Beyond Global, Inc. (NASDAQ: FBYD) traded higher on Tuesday after the company announced its placement on the preliminary list for possible inclusion in the Russell 2000 Index. FTSE Russell p...
Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus
Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.
Milestones Over Sales: The Sanofi Partnership Now Drives Novavax's Outlook
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation
Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.
AI won't cure cancer, says Sanofi CEO
Paul Hudson, CEO of pharmaceuticals giant, Sanofi discusses the benefits and limitations of implementing AI across the healthcare sector.
Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation
Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financial...
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financia...
Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale
Sanofi's Paris HQ raided over tax fraud probe tied to Societe Generale financing. Read more here.
Sanofi (SNY) Investigated for Tax Fraud and Money Laundering
Sanofi (SNY) Investigated for Tax Fraud and Money Laundering
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria
Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria
Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria
Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria in a decade
Please provide the article or its content so I can generate the meta description as per your instructions.
Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for modera...
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly re...